About US
Contact us
-
SFDA Chief of Discipline Inspection Group Yu Xiancheng visits the Netherlands Health Care Inspectorate and signs MOUOn April 19, 2012, Yu Xiancheng, Chief of Discipline Inspection Group of the State Food and Drug Administration (SFDA), signed the Memorandum of Understanding Between the State Food and Drug Administr2012/5/11
-
A strike against sales-rep OT as Lilly, Abbott win appealDon't count pharma out in the sales-rep overtime fight. As Pharmalot reports, a U.S. appeals court has denied overtime for Eli Lilly ($LLY) and Abbott Laboratories ($ABT) sales reps. The reps quali2012/5/11
-
Lipitor copy powers a surge in Ranbaxy sales, profitsWhat a difference generic Lipitor can make. Ranbaxy Laboratories' first-quarter earnings soared on its launch of the cholesterol drug copycat, to 12.47 billion rupees--$234.3 million--from 3.04 bil2012/5/10
-
FDA panel nixes Regeneron's Arcalyst for goutRegeneron ($REGN) may not be able to aim Aracalyst at the lucrative gout market. The would-be indication was shot down in an FDA advisory committee meeting, putting a new approval in doubt. Arcalyst i2012/5/10
-
Europe may be austere, but it's also hiring in pharmaPharma is hiring. Not in the U.S. so much, nor in hot spots like the Asia Pacific region. No, according to a report from corporate recruiters ZRG Partners, the biggest increase in pharma hiring for2012/5/9
-
Docs riled by FDA's proposal to open up drug accessThe FDA wants to knock down obstacles to certain drug treatments. It's an idea doctors abhor and insurers cautiously embrace, and one the FDA has floated before, if in other forms. If it reclassifi2012/5/9
-
Pharma continues parachute-building for patent cliffLast month was a big one for pharma dealmaking, as anyone following the industry knows well. The list of deals, bids and potential deals is long--$33 billion long, as Dealogic tells the Financial Time2012/5/8
-
Roche gives up on anticipated 'good cholesterol' drugRoche's ($RHHBY) once-promising "good cholesterol" drug candidate is now history. The Swiss company stopped development of dalcetrapib after it fell short in a late-stage trial. Coupled with the failu2012/5/8
-
Pfizer, Lilly, AstraZeneca giving NIH abandoned drugsThree of the world's largest drug manufacturers are going to empty out their closets and turn over research on unsuccessful drugs to the National Institutes of Health. The idea is that federally funde2012/5/7
-
India's Cipla puts fire-sale prices on cancer drugsIn what appears as a full-on assault on the pricing structure of Western drugmakers, Indian genericsmaker Ciplawill sell its copies of cancer drugs for a fraction of their branded counterparts. Cipla2012/5/7